What Is a Full-Panel Kratom COA? A Practical Lab-Testing Checklist

The short answer

A full panel kratom COA should mean more than a
one-page potency result. In ordinary quality discussions, the phrase
usually refers to a certificate of analysis that addresses the product’s
identity, relevant alkaloids and reasonably foreseeable contaminants.
But there is no single federal chart that defines one universal “full
panel” for every kratom powder, capsule, tea, extract, gummy or
beverage.

The appropriate testing package depends on the material,
manufacturing process, product format, supply chain, specifications and
applicable law. A defensible review may include:

• botanical identity;
• mitragynine and 7-OH measurements;
• aerobic microbial count, yeast and mold, and other microbial
  indicators;
• pathogen testing, commonly including Salmonella and
  specified E. coli;
• toxic elements such as lead, arsenic, cadmium and mercury;
• a justified pesticide-residue panel;
• mycotoxins when the ingredient and storage risks warrant it;
• residual solvents for extracts or solvent-processed materials;
• moisture or water activity where stability and microbial control
  depend on them;
• product-specific checks such as capsule fill weight, blend
  uniformity or individual-unit consistency.

That list is a framework, not a promise that every test is required
for every product. It also is not complete merely because a vendor
places the words FULL PANEL at the top of a report.

A useful COA must answer five questions:

1. What was tested?
2. Which lot was represented?
3. Which methods, units and reporting limits were
   used?
4. What acceptance criteria applied?
5. Do the results support the claim being made?

The most important principle is simple: the scope of the
evidence should match the scope of the claim.

If you are checking a report for the first time, begin with Kiody’s
guide to verifying a
lot-specific kratom COA. When a result uses ND or a less-than sign,
review what
ND, LOD and LOQ mean on a kratom COA before treating the value as
zero.

“Full panel” is not a
universal term

Laboratories, manufacturers and retailers do not always use “full
panel” the same way.

One laboratory may use the phrase for an alkaloid assay plus four
heavy metals. Another may mean alkaloids, metals, microbiology,
pathogens and pesticides. A third may include residual solvents but omit
identity testing. Some reports combine several disciplines into one COA;
others issue separate reports for chemistry and microbiology.

Therefore, the phrase itself is not evidence. The analyte list is
evidence.

A careful reader should replace this question:

“Is it full-panel tested?”

with these questions:

“Which analytes and organisms were tested, on which lot, using which
methods, at what reporting limits, and against which
specifications?”

This distinction follows the logic of federal dietary-supplement
current good manufacturing practice requirements. Those rules do not
define one fixed panel for all products. They require firms within their
scope to establish specifications and use appropriate, scientifically
valid tests or examinations to determine whether selected specifications
are met. Finished-batch verification must address identity, purity,
strength, composition and contamination specifications through an
appropriately documented program. 21
CFR §111.70, 21
CFR §111.75 and 21
CFR §111.320.

FDA’s current position is that kratom is not lawfully marketed as a
dietary supplement or conventional food additive in the United States.
Referring to Part 111 in this guide explains useful quality-system
concepts; it does not imply FDA approval, lawful dietary-supplement
status or acceptance of a particular kratom product. FDA
and Kratom.

A COA is a
report, not the whole quality system

A certificate of analysis is a snapshot of reported testing for a
sample. It is not the same thing as:

• a product specification;
• a sampling plan;
• a batch-production record;
• a sanitation program;
• supplier qualification;
• process validation;
• a stability study;
• a recall system;
• a regulatory approval;
• a guarantee that every package is identical to the sample.

A polished COA can still be weak evidence if the sample was not
representative, the lot number does not match, the method was unsuitable
for the matrix, the reporting limit was too high, or the product changed
after testing.

Those questions are explored in greater depth in Kiody’s guides to sample
chain of custody and why kratom
laboratory results can differ.

The reverse is also true. A responsible quality system may produce
several technical records instead of one attractive “full-panel” sheet.
The evidence may be stronger even if it is less convenient to
display.

Consumers need not become laboratory auditors. They should, however,
understand what the report can and cannot establish.

The ten
building blocks of a strong testing package

1.
Identity: is the material what the label says it is?

Identity testing asks whether the botanical ingredient is consistent
with Mitragyna speciosa rather than a substituted, mixed or
misidentified material.

Identity may be evaluated through one or more approaches:

• macroscopic or organoleptic examination;
• microscopy;
• chemical fingerprinting;
• high-performance thin-layer chromatography;
• chromatographic comparison with reference material;
• DNA-based methods when the material and question are suitable;
• a scientifically justified combination of methods.

No single method answers every identity question. Fine grinding may
remove visible plant structures needed for some microscopic
distinctions. Processing can degrade DNA. A targeted alkaloid assay can
show that certain compounds are present without proving exclusive
botanical identity. Chemical similarity may not identify every
undeclared ingredient.

The federal quality-system framework requires at least one
appropriate identity test or examination for each dietary ingredient
component unless FDA grants a petitioned exemption. It also recognizes
organoleptic, macroscopic, microscopic, chemical and other
scientifically valid methods. 21
CFR §111.75.

A potency-only COA is not automatically an identity report. If a
document lists mitragynine but contains no identity conclusion, do not
invent one.

2.
Alkaloid profile: what was measured, and on what basis?

Kratom alkaloid panels commonly report mitragynine and 7-OH. Some
methods report additional alkaloids, but the number of compounds varies
among laboratories and methods.

For each reported alkaloid, review:

• analyte name;
• numerical result or qualified result;
• unit;
• dry-weight or as-received basis;
• method identification;
• reporting limit;
• specification, if one is used;
• sample type;
• preparation or dilution notes.

Common units include percent by weight, milligrams per gram,
milligrams per kilogram and milligrams per serving. Those are not
interchangeable without the relevant product weight and calculation
basis.

Useful mass conversions for solid products include:

• 1% = 10 mg/g;
• 0.1% = 1 mg/g;
• 1 mg/g = 1,000 mg/kg;
• 1 mg/kg is approximately 1 part per million by mass.

But a percentage of the total product cannot be
directly substituted for a percentage of the total alkaloid
fraction. Likewise, a milligram-per-serving threshold cannot be
evaluated from percent alone unless the serving mass and formulation are
known.

Current legal thresholds make this especially important. Federal
authorities have proposed temporarily scheduling 7-OH above specified
thresholds, and the comment period was extended through September 10,
2026. That proceeding is distinct from DEA’s effective August 26, 2026
temporary Schedule I placement of mitragynine pseudoindoxyl, MGM-15 and
MGM-16. A COA should not blur ordinary botanical mitragynine, naturally
minor 7-OH, concentrated 7-OH and separately scheduled manufactured
derivatives. HHS
7-OH comment-period extension and DEA
MGPI/MGM-15/MGM-16 order.

3.
Microbial enumeration: how much general microbial growth was found?

Microbial enumeration methods estimate quantities such as:

• total aerobic microbial count;
• total yeast and mold count;
• coliforms or Enterobacteriaceae, depending on the program;
• other indicator organisms selected for the product and process.

Results may be reported as colony-forming units per gram, most
probable number per gram, or a qualified value such as less than the
method’s reporting limit.

Enumeration results are different from pathogen presence/absence
results. A low total aerobic count does not by itself prove that
Salmonella is absent. A yeast-and-mold count does not identify
every fungal species or quantify mycotoxins. A result labeled “pass” has
meaning only when the specification and method are known.

FDA’s Bacteriological Analytical Manual contains methods and
laboratory principles used for food microbiology, including enumeration
and pathogen procedures. It is a method resource, not a kratom-specific
universal panel or acceptance table. FDA
Bacteriological Analytical Manual.

4.
Pathogens: was a specified organism detected in the tested portion?

Pathogen tests commonly report a qualitative result such as:

• absent in 25 grams;
• not detected in 25 grams;
• negative;
• detected;
• positive.

The test portion matters. “Not detected in 25 g” does not mean a
laboratory examined every gram in a production lot. It means the
specified organism was not detected in the tested portion under the
stated method and conditions.

For a pathogen result, check:

• the organism;
• the analytical portion size;
• whether enrichment was used;
• the method;
• whether confirmation was performed when required;
• the exact result wording;
• the sample and lot identity.

FDA has documented kratom products contaminated with
Salmonella and concerning levels of heavy metals. That history
is one reason a potency-only panel should not be mistaken for
comprehensive contaminant evidence. FDA
and Kratom and FDA’s
2018 mandatory kratom recall.

5. Toxic
elements: which elements were measured?

The phrase “heavy metals tested” is incomplete without an analyte
list. Common panels include:

• lead;
• arsenic;
• cadmium;
• mercury.

Some panels report total arsenic or total mercury. Others may include
speciation, such as inorganic arsenic or methylmercury, when
appropriate. Total-element and species-specific results answer different
questions and should not be substituted for one another.

Review:

• the exact element or species;
• result and unit;
• reporting limit;
• method;
• sample basis;
• specification;
• whether “ND” is defined.

FDA’s Elemental Analysis Manual provides analytical methods and
quality-control information for elements in foods and related products.
It illustrates why sample preparation, instrument performance, blanks,
calibration and reporting limits matter. It does not establish one
universal kratom limit. FDA
Elemental Analysis Manual.

6.
Pesticide residues: how broad and appropriate was the screen?

A COA that says “pesticides: pass” without naming analytes is
difficult to evaluate. Pesticide screens can differ substantially
in:

• number of compounds;
• compound classes;
• extraction method;
• instrument platform;
• reporting limits;
• matrix validation;
• applicable tolerances or internal specifications.

“300 pesticides tested” is not automatically stronger than “200
pesticides tested.” A longer list may contain compounds irrelevant to
the supply chain while omitting a locally important pesticide or using
reporting limits that are too high for the intended decision.

A risk-based panel should consider cultivation region, agricultural
practices, prior findings, supplier history, regulatory requirements and
the laboratory’s ability to analyze the product matrix.

Consumers generally cannot audit a pesticide method from a marketing
page. They can still check whether the COA provides an analyte list,
actual or qualified results, units, reporting limits and a traceable
lot.

7.
Mycotoxins: toxins are not the same as mold counts

Mycotoxins are chemical substances produced by certain molds under
some conditions. Common analytical targets may include aflatoxins and
ochratoxin A, depending on the material and risk assessment.

A yeast-and-mold count and a mycotoxin assay are not
interchangeable:

• a mold count estimates viable organisms under the test
  conditions;
• a mycotoxin test measures selected chemical toxins;
• low viable mold does not prove that previously produced toxin is
  absent;
• detecting mold does not establish that a listed mycotoxin is
  present.

A report should identify each toxin or defined sum, its result, unit,
reporting limit and specification. “Mycotoxins passed” without the scope
is not enough to reconstruct the decision.

8. Residual
solvents: especially relevant to extracts

Residual-solvent testing is most relevant when a solvent is used or
may reasonably be introduced during extraction, purification, flavor
processing or manufacturing.

A plain leaf powder and a concentrated extract do not necessarily
need identical solvent panels. For an extract, useful questions
include:

• Which solvents were used or reasonably foreseeable?
• Does the laboratory’s panel include them?
• Was the method validated or verified for that matrix?
• Are results reported per mass of product, per serving or on another
  basis?
• Are applicable limits identified?

A report stating only “solvents: ND” is incomplete unless the
analytes and reporting limits are available. “ND” means not detected at
or above a stated method boundary—not proof of absolute zero.

9.
Moisture and water activity: related, but not the same measurement

Moisture content estimates how much water is in a material. Water
activity describes the availability of water for microbial growth and
chemical change. Two powders with similar moisture percentages can have
different water activity because the water may be bound differently.

These measurements can support:

• drying and storage controls;
• packaging selection;
• shelf-life investigations;
• microbial-risk evaluation;
• comparisons among lots.

Neither number alone proves shelf life. A stability or expiration
claim should be supported by an appropriate program that considers the
packaged product over time.

10. Finished-product
and unit-level checks

Ingredient testing does not automatically establish every property of
the finished product.

Depending on format, additional checks may include:

• capsule count and average fill weight;
• fill-weight variation;
• blend homogeneity;
• individual-piece uniformity for gummies or tablets;
• net contents;
• pH for liquids;
• package integrity;
• label reconciliation;
• organoleptic or physical examination;
• finished-product alkaloid or contaminant confirmation.

For example, a bulk extract COA does not prove that each gummy
received an equivalent amount. A powder COA does not establish that a
later flavored beverage remained homogeneous, stable or uncontaminated
after processing.

The evidence should follow the material through manufacture, not stop
at the most convenient supplier document.

What a strong COA should
show

A readable report usually includes the following elements.

Product and sample
identification

• product or sample name;
• matrix or product type;
• lot or batch number;
• unique laboratory sample ID;
• client or submitting firm;
• sample-received date;
• testing dates;
• report date;
• report or revision number.

Laboratory identification

• legal laboratory name;
• address or contact details;
• authorized signatory or approval;
• accreditation mark or claim, when applicable;
• method references;
• page numbers and total pages.

Results

• analyte or organism;
• actual numerical result or defined qualifier;
• unit;
• reporting, detection or quantitation limit;
• specification or action limit, when the laboratory is making a
  conformity decision;
• pass/fail or other decision, if requested;
• necessary comments, dilution notes or calculation basis.

Integrity controls

• a consistent lot number across pages;
• no unexplained missing pages;
• revision history when a report was amended;
• a verification link, QR code or direct laboratory confirmation
  route;
• signatures and dates consistent with the laboratory’s
  procedure.

A QR code alone does not make a COA authentic. It should resolve to a
secure, relevant report or verification system, not merely a vendor
homepage.

Raw-material
testing versus finished-product testing

This is one of the most important distinctions in COA review.

Raw botanical material

Testing incoming leaf or powder can provide evidence about that
component before manufacture. It may help evaluate identity, alkaloids
and contaminants present at receipt.

It does not automatically account for:

• contamination introduced during later handling;
• blending errors;
• incorrect capsule filling;
• added ingredients;
• extract standardization;
• heat or storage changes;
• package failures;
• label mix-ups.

Intermediate material

An extract concentrate, blend or premix may be tested before final
packaging. This can be valuable process evidence, but it may not
represent the finished unit if dilution, flavoring, filling or packaging
occurs afterward.

Finished product

Finished-product testing evaluates the product in the form released
for sale. It can address risks created by formulation and manufacturing,
but even a finished-product result depends on a representative sampling
plan.

The strongest answer is rarely “raw testing or finished testing.” A
risk-based program connects supplier qualification, incoming component
controls, in-process monitoring and finished-batch verification.

Testing frequency is a separate decision. See How
Often Should Kratom Be Tested? for the difference between testing
every lot, periodic verification and event-triggered testing.

One lot, one report:
why matching matters

A current-looking COA is not necessarily the COA for the package in
hand.

Compare the package and report for:

• lot or batch number;
• product name;
• product format;
• flavor or variant;
• concentration;
• package size where relevant;
• manufacture or expiration information;
• report revision.

Do not accept “representative COA” as equivalent to a lot-specific
result unless the vendor clearly explains the program and the claim
being supported. A report from a different lot may illustrate a testing
format, but it does not establish the result for the current lot.

Likewise, a raw-material lot report should not be relabeled as a
finished-product report. Traceability must be documented, not
assumed.

Reporting
limits can determine whether a test is useful

Suppose a specification requires less than 0.50 mg/kg of an analyte,
but the laboratory’s reporting limit is 2.0 mg/kg. A result of “ND
<2.0 mg/kg” does not establish compliance with the 0.50 mg/kg
specification. The test was not sensitive enough to answer that
question.

For each analyte, compare:

reporting limit → result → specification

The reporting limit should be low enough to support the intended
decision. This matters for contaminants and for low-level alkaloid
thresholds.

Also check whether the laboratory defines:

• ND or not detected;
• LOD or detection limit;
• LOQ or quantitation limit;
• RL or reporting limit;
• estimated or trace values;
• dry-weight correction;
• measurement uncertainty;
• conformity or decision rules.

An “ND” result without a boundary is less informative than a defined
result such as “not detected at or above 0.10 mg/kg.”

Accreditation helps—but
scope matters

ISO/IEC 17025 accreditation can provide evidence that a laboratory’s
management system and specified technical activities were assessed by an
accreditation body. It is not a universal seal covering every test the
laboratory offers.

A reviewer should verify:

• the laboratory name and location;
• accreditation status;
• certificate number;
• expiration or surveillance status;
• accrediting body;
• scope of accreditation;
• method or discipline;
• analyte;
• product matrix or field of testing.

A laboratory may be accredited for microbiology but not alkaloid
potency, or for environmental water rather than botanical powder. A
certificate without the scope can create false confidence.

FDA’s Laboratory Accreditation for Analyses of Foods program likewise
emphasizes laboratory accreditation, sampling and method requirements
for testing performed under that specific federal program. Participation
in one program does not make every laboratory result interchangeable or
turn a kratom COA into FDA approval. FDA
LAAF program.

Product format
changes the appropriate panel

Leaf powder

A leaf-powder testing package commonly emphasizes identity,
alkaloids, microbiology, pathogens, toxic elements, pesticides,
mycotoxins and moisture-related controls. The exact selection should
follow documented risk and specifications.

Capsules

Capsules add finished-unit questions such as fill weight, count,
shell ingredients, cross-contact and blend consistency. A bulk powder
report alone does not verify every finished capsule or the accuracy of
the label count.

Extracts

Extracts add concentration, dilution, residual-solvent and
matrix-effect questions. A method that performs acceptably for leaf
powder may not automatically perform acceptably for a viscous liquid or
concentrated resin.

Gummies and tablets

These formats add individual-unit uniformity, added ingredients and
finished-product matrix challenges. Composite testing can estimate a
batch average while concealing piece-to-piece variation.

Beverages and shots

Liquids can require attention to pH, preservatives, fill volume,
emulsion or suspension uniformity, container compatibility and
stability. Testing the bulk mixture before filling may not answer every
packaged-product question.

Concentrated 7-OH products

These should not be described as ordinary leaf merely because they
use the word “kratom.” Their concentration, formulation, risk profile
and legal treatment can differ materially. Kiody does not sell
concentrated 7-OH.

MGPI, MGM-15 and MGM-16

These named manufactured derivatives are federally Schedule I under
DEA’s temporary order effective August 26, 2026. A “full panel” does not
make a scheduled product lawful. Do not group their legal status with
ordinary botanical leaf. DEA
temporary scheduling order.

Six fictional COA reviews

The following examples are invented for education. They do not
describe Kiody lots, laboratories or products.

Example 1: the
potency-only “full panel”

Report: Mitragynine 1.22%; 7-OH <LOQ. The vendor
calls it “full panel tested.”

What it supports: The report may provide limited
alkaloid evidence if the lot, method, unit, basis and reporting limit
are clear.

What is missing: Identity, microbiology, pathogens,
metals, pesticides, mycotoxins and other relevant contaminant
evidence.

Conclusion: Do not call the report a comprehensive
panel solely because it measured two alkaloids.

Example 2:
the multi-page report with the wrong lot

Package lot: KP-260801.
COA lot: KP-260701.

What it supports: Results for the tested KP-260701
sample.

What it does not support: The specific KP-260801
package.

Next step: Request the matching report or a
documented explanation of how the lots relate. Do not silently change a
digit or assume it is a typo.

Example
3: many pesticide analytes, weak reporting limits

Claim: “Tested for 400 pesticides.”
Report: Analyte list is present, but many reporting
limits exceed the vendor’s own specifications.

What it supports: The laboratory attempted a broad
screen.

Problem: ND results above the acceptance limits
cannot demonstrate that the lower specifications were met.

Conclusion: Analyte count is not enough; method
sensitivity must support the decision.

Example 4: raw
extract COA attached to gummies

COA: Bulk extract passed alkaloid and metals
testing.
Product: Finished gummies containing extract, sugar,
flavors and acids.

What it supports: Evidence about the submitted bulk
extract.

What it does not establish: Finished-gummy microbial
condition, individual-piece uniformity, final alkaloid concentration or
contamination introduced during production.

Conclusion: Supplier evidence may be valuable, but
it is not automatically a finished-product COA.

Example 5: pathogen
negative, no portion size

Report: “Salmonella: Negative.”

What is unclear: Test portion, method, enrichment
and reportable conclusion.

Why it matters: “Not detected in 25 g” conveys more
information than an unexplained “negative.”

Next step: Request the complete report or method
details before interpreting the result.

Example 6: a
genuinely useful testing package

Report set: Matching lot number; botanical identity;
alkaloids with dry-weight basis and reporting limits; microbial
enumeration; Salmonella and specified E. coli with
portion sizes; four named toxic elements; analyte-level pesticide and
mycotoxin results; moisture and water activity; methods; specifications;
report dates; authorized approval; and a laboratory-verification
route.

What it supports: A broad, traceable set of results
for the tested sample and identified lot.

What it still does not prove: Universal safety, FDA
approval, legal status everywhere, absence of every untested substance,
or perfect uniformity across every package.

Conclusion: Strong evidence is specific about both
its findings and its limits.

A 15-step full-panel COA
review

Step 1: Match the lot

Compare the package lot or batch number with every report page.

Step 2: Match the product
format

Confirm that a powder report is not being presented as a gummy,
capsule, liquid or finished-extract report.

Step 3: Check the report
identity

Look for a unique laboratory sample number, report number, version
and complete page count.

Step 4: Verify dates

Review received, tested and reported dates. Future dates, impossible
sequences or unexplained old reports deserve follow-up.

Step 5: Inventory the
sections

List what is actually included: identity, alkaloids, microbes,
pathogens, elements, pesticides, mycotoxins, solvents and
product-specific checks.

Step 6: Read every analyte
name

Do not rely on headings such as “metals” or “pesticides.” Confirm the
individual analytes.

Step 7: Confirm units

Check percent, mg/g, mg/kg, CFU/g, MPN/g, per serving and
presence/absence wording.

Step 8: Find reporting limits

Determine what ND, <LOD and <LOQ mean on that report.

Step 9: Identify
specifications

Find the acceptance limit and its source. A pass/fail label without a
criterion is hard to audit.

Step 10:
Compare sensitivity with specifications

Make sure the reporting limit is capable of supporting the pass
decision.

Step 11: Review methods

Confirm that methods are identified and appropriate for the product
matrix and intended use.

Step 12: Check accreditation
scope

Verify the relevant laboratory location, discipline, method, analyte
and matrix—not only the logo.

Step 13:
Distinguish raw from finished evidence

Identify where in the supply and production chain the sample was
collected.

Step 14: Authenticate the
report

Use a laboratory verification system or contact route when available.
Treat vendor-hosted PDFs as documents to verify, not self-authenticating
proof.

Step 15: Record gaps and
decisions

Write down what the report establishes, what remains unknown and what
follow-up is required. Avoid upgrading missing evidence into a pass by
assumption.

Twenty-five warning signs

One warning sign does not automatically prove misconduct. It does
justify closer review.

1. “Full panel” appears without an analyte list.
2. The lot number is missing.
3. The package and report lots do not match.
4. Only mitragynine is reported.
5. 7-OH is omitted without explanation.
6. “Heavy metals passed” appears without naming elements.
7. “Pesticides passed” appears without analytes or limits.
8. ND is not defined.
9. Units are missing.
10. Reporting limits are absent.
11. Reporting limits exceed specifications.
12. Dry-weight and as-received results are mixed without
    explanation.
13. A percentage of product is confused with a percentage of total
    alkaloids.
14. A per-serving claim lacks a defined serving mass or volume.
15. A raw-material COA is marketed as finished-product testing.
16. The report omits the product matrix.
17. The method is not identified.
18. The laboratory name or location is unclear.
19. An accreditation logo appears without a verifiable scope.
20. Pages are missing or inconsistently numbered.
21. Results or dates appear altered, covered or reformatted.
22. The report has an unexplained revision.
23. A QR code leads only to a sales page.
24. “FDA approved” or “FDA certified” is inferred from testing.
25. The report is used to claim guaranteed safety or legality
    everywhere.

Questions a
transparent seller should be able to answer

A seller should not need to disclose confidential supplier contracts
to answer basic product-evidence questions. Useful answers include:

• Is this the COA for the lot currently offered?
• Was the tested sample raw material, an intermediate or the finished
  product?
• Who selected and submitted the sample?
• Which laboratory performed each panel?
• Which tests are within the laboratory’s accreditation scope?
• What does ND mean on this report?
• Why were these analytes selected?
• Which specifications were used?
• How are results outside specification handled?
• How are complaints and recalls linked to the lot?
• How often is the product tested?
• How are product-format risks addressed?
• Does the product contain extract, enhanced material, concentrated
  7-OH or manufactured derivatives?

Honest answers may include limitations. “This analyte was not
included” is more useful than an unsupported claim that a report tests
for everything.

Frequently asked questions

Does
“third-party tested” mean full-panel tested?

No. It generally means testing was performed by an outside
laboratory, but it does not identify the panel, sample, method,
specifications, laboratory relationship or accreditation scope.

Is there
one legally required national kratom panel?

No single federal kratom-specific chart defines a universal panel for
every product. Applicable state rules vary, and FDA maintains that
kratom is not lawfully marketed as a dietary supplement or conventional
food additive. Testing design should not be used to imply federal
approval.

Is an alkaloid COA enough?

An alkaloid report may answer defined composition questions. It does
not automatically address identity, microbes, pathogens, metals,
pesticides, mycotoxins, solvents or finished-product uniformity.

How many pages
should a full-panel COA have?

There is no ideal page count. Completeness depends on the
information, not the number of pages.

Should mitragynine and
7-OH both appear?

If a seller makes claims about both compounds or relies on a 7-OH
threshold, the evidence should report the relevant analytes with
suitable limits and units. An omitted analyte should not be treated as
zero.

Does “ND” mean none is
present?

No. It means the analyte was not detected or reported at or above the
applicable method boundary under the test conditions. The report should
define that boundary.

Does
passing one sample prove the entire lot passed?

It supports conclusions about the submitted sample.
Representativeness depends on the sampling plan, lot uniformity and
chain of custody.

Can two
laboratories produce different results?

Yes. Sampling, preparation, calibration, method selectivity, moisture
correction, reporting limits and normal analytical variation can all
affect results. Differences should be investigated, not automatically
labeled fraud.

Is a
laboratory’s accreditation certificate enough?

No. Review the scope to determine whether the relevant test, analyte,
method and matrix are included.

Does a laboratory
need to be FDA approved?

“FDA-approved laboratory” is often misleading in this context. FDA
administers specific laboratory programs, but a private COA does not
become FDA approval of the laboratory, product or kratom marketing.

Are microbial
counts the same as pathogen tests?

No. Enumeration estimates general microbial populations. Pathogen
tests address specified organisms using defined methods and
portions.

Does low yeast and
mold prove no mycotoxins?

No. Viable mold counts and selected chemical toxin measurements
answer different questions.

Are four heavy metals
always enough?

Lead, arsenic, cadmium and mercury are common targets, but an
appropriate program depends on risk, specifications and applicable
requirements. The four-analyte list should not be marketed as testing
for every possible element.

Does a
large pesticide panel guarantee better testing?

No. Relevance, method performance, reporting limits and matrix
suitability matter alongside analyte count.

Does
botanical leaf need residual-solvent testing?

The need depends on processing and reasonably foreseeable exposure.
Solvent testing is particularly relevant to extracts and
solvent-processed materials.

Is moisture the same as
water activity?

No. Moisture estimates water quantity; water activity estimates how
available that water is for microbial growth and other changes.

Can a supplier
COA replace independent testing?

Supplier COAs can be part of a qualified program. Under the Part 111
framework, reliance on a supplier COA for non-identity component
specifications requires documented supplier qualification, confirmation
of reliability and periodic reconfirmation. It is not blind
reliance.

Must every
finished batch receive every test?

Testing frequency should follow applicable law and a documented,
scientifically justified program. Part 111 permits selected
finished-batch verification based on a sound statistical sampling plan
while requiring documentation that the selected specifications verify
the production and process-control system. This is not permission to
omit foreseeable risks without justification.

Can one COA
cover several flavors or strengths?

Only if the relationship is scientifically and procedurally
justified. Different formulations can create different matrices,
concentrations and contaminant risks.

Is a
current report automatically relevant to my package?

No. The lot, product and format must match. A newly dated generic
report may still concern a different batch.

Does a full panel
establish shelf life?

No. A release test is a point-in-time result. Shelf life requires
evidence about the packaged product over time under defined
conditions.

Does
full-panel testing make kratom medically safe?

No. A COA cannot determine whether use is safe for a particular
person, rule out interactions, or convert a product into an approved
treatment.

Does full-panel
testing make a product legal?

No. Testing and legal status are separate questions. Federal, state
and local laws may regulate or prohibit products based on ingredients,
concentrations, age, format, labeling or location.

Are
concentrated 7-OH products the same as leaf powder?

No. Concentrated or enhanced 7-OH products can differ materially in
composition, risk and legal treatment. Kiody does not sell concentrated
7-OH.

Are
MGPI, MGM-15 and MGM-16 ordinary kratom alkaloids for sales
purposes?

They should not be presented as ordinary botanical leaf. DEA
temporarily placed those three named substances in Schedule I effective
August 26, 2026.

What is the
best one-sentence request for a seller?

Ask: “Please provide the complete, lot-matching reports with
analytes, methods, units, reporting limits and specifications for the
product currently offered.”

A reusable review record

Use this template for each product and lot:

Product:
Format:
Package lot:
COA lot:
Laboratory sample ID:
Sample received:
Testing dates:
Report date and revision:
Raw, intermediate or finished sample:
Sampler/submitting party:
Identity method and conclusion:
Mitragynine result, unit and basis:
7-OH result, unit and basis:
Additional alkaloids:
Microbial enumeration:
Pathogen tests and portions:
Toxic elements:
Pesticide analytes:
Mycotoxins:
Residual solvents:
Moisture/water activity:
Finished-unit checks:
Reporting limits shown: Yes / No
Specifications shown: Yes / No
Methods shown: Yes / No
Accreditation scope verified: Yes / No / Partial
Laboratory authentication completed: Yes / No
Missing evidence:
Follow-up requested:
Reviewer:
Review date:
Disposition: Accept / Hold / Investigate / Reject / Not
enough information

This record does not replace a formal quality procedure. Its purpose
is to stop the reviewer from treating a marketing phrase as a complete
technical conclusion.

The bottom line

“Full panel” should be the beginning of a conversation, not the
end.

A meaningful kratom testing package identifies the product and lot,
uses methods suitable for the matrix, reports actual results and limits,
and covers the specifications and foreseeable hazards relevant to that
product. A powder, capsule, extract, gummy and beverage do not
necessarily require identical evidence. Raw-material and
finished-product reports are not interchangeable. One tested sample does
not prove every package, every untested analyte or universal safety.

The most trustworthy COA is not the one with the boldest heading. It
is the one that lets a careful reader trace:

product → lot → sample → method → result → specification → decision